Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Chandra Bhagat Pharma's Revenue for the
six
months ended in Mar. 2026 was ₹907 Mil. Chandra Bhagat Pharma's average Accounts Receivable for the
six
months ended in Mar. 2026 was ₹423 Mil.
Hence, Chandra Bhagat Pharma's Receivables Turnover for the
six
months ended in Mar. 2026 was 2.14.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Chandra Bhagat Pharma Receivables Turnover Related Terms
Chandra Bhagat Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Chandra Bhagat Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:542934 vs MCK, COR, CAH: Receivables Turnover Comparison
For the Medical Distribution subindustry, Chandra Bhagat Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chandra Bhagat Pharma Receivables Turnover vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Chandra Bhagat Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Chandra Bhagat Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chandra Bhagat Pharma (BOM:542934) has a Receivables Turnover of 2.14 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Chandra Bhagat Pharma and its competitors. According to the industry distribution chart, Chandra Bhagat Pharma ranks #92 out of 121 companies in the Medical Distribution industry, placing it in the top 76%.
Is Chandra Bhagat Pharma's Receivables Turnover too high?
Chandra Bhagat Pharma's current Receivables Turnover is 2.14. The Medical Distribution industry median Receivables Turnover is 4.81. Chandra Bhagat Pharma's value of 2.14 is 55.5% below this industry median. Based on the distribution chart, Chandra Bhagat Pharma ranks #92 out of 121 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Chandra Bhagat Pharma has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chandra Bhagat Pharma's Receivables Turnover compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Chandra Bhagat Pharma ranks #92 out of 121 companies for Receivables Turnover. This places Chandra Bhagat Pharma in the lower half of its industry. The industry median Receivables Turnover is 4.81. Chandra Bhagat Pharma's value of 2.14 is 55.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Distribution company?
The median Receivables Turnover among Medical Distribution companies is 4.81, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chandra Bhagat Pharma's current Receivables Turnover of 2.14 is 55.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Chandra Bhagat Pharma and its competitors. For the Medical Distribution industry, the median Receivables Turnover is 4.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chandra Bhagat Pharma's current Receivables Turnover is 2.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandra Bhagat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Chandra Bhagat Pharma (BOM:542934) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹67.21, compared to a current price of ₹47.88 — trading 28.8% below its estimated fair value. The current Receivables Turnover is 2.14 and 55.5% below the Medical Distribution industry median of 4.81. Chandra Bhagat Pharma's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Chandra Bhagat Pharma (BOM:542934), the current Receivables Turnover is 2.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chandra Bhagat Pharma (BOM:542934) Overvalued in 2026?
Based on GuruFocus' analysis, Chandra Bhagat Pharma stock appears to be undervalued.
The current stock price of ₹47.88 is trading 28.8% below its estimated GF Value™ of ₹67.21.
GuruFocus considers Chandra Bhagat Pharma to be Modestly Undervalued.
Key valuation signals for BOM:542934:
Receivables Turnover: 2.14
GF Value™: ₹67.21 vs. price of ₹47.88 (28.8% below fair value)
Industry Position: 55.5% below the Medical Distribution median (#92 of 121)
No single metric tells the full story. See the BOM:542934 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chandra Bhagat Pharma Ltd is a pharmaceutical company marketing pharmaceutical, critical care, and health care products across the globe. The company deals in many categories of pharmaceutical products like anticancer, cardiovascular, anti-infective, etc. It offers various forms of pharmaceutical products, like oral solids. tablets, capsules, liquid orals, syrup suspension, injections, liquid, powder, etc. Additionally, the company is also engaged in promoting and marketing of Active Pharmaceutical Ingredients (API's) in India.
66GF Score
Get the complete analysis for BOM:542934
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542934 has been successfully added to your 
